Free Trial

Healthcare and Medical Stocks List

This page shows information about the 50 largest healthcare and medical sector stocks including Eli Lilly and Company, Novo Nordisk A/S, UnitedHealth Group, and Johnson & Johnson. Learn more about health care stocks.

Eli Lilly and Company logo

#1 - Eli Lilly and Company

NYSE:LLY - See Stock Forecast
Stock Price:
$905.41 (-$36.19)
Market Cap:
$894.90 billion
P/E Ratio:
133.3
Dividend Yield:
0.55%
Consensus Rating:
Moderate Buy (0 Strong Buy Ratings, 16 Buy Ratings, 3 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$858.72 (-5.2% Downside)
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of Eli Lilly and Company Stock

Pros

  • Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide, showcasing a strong commitment to innovation and growth in the healthcare sector.
  • The company offers a diverse range of pharmaceutical products, including insulin brands like Basaglar, Humalog, and Humulin, catering to a wide market and ensuring revenue stability.
  • Recent developments in Eli Lilly's product portfolio, such as the introduction of new insulin formulations like Humalog U-200 and Humalog Mix 50/50, demonstrate ongoing research and development efforts to meet evolving healthcare needs.

Cons

  • While Eli Lilly has a diverse product portfolio, the competitive nature of the pharmaceutical industry may pose challenges in maintaining market share and profitability over time.
  • Regulatory changes and healthcare policies can impact Eli Lilly's operations and financial performance, leading to uncertainties in the investment landscape.
  • Investors should consider the potential risks associated with investing in pharmaceutical companies, such as clinical trial failures, patent expirations, and market competition, which could affect Eli Lilly's stock value.
Novo Nordisk A/S logo

#2 - Novo Nordisk A/S

NYSE:NVO - See Stock Forecast
Stock Price:
$135.42 (-$5.45)
Market Cap:
$607.70 billion
P/E Ratio:
46.7
Dividend Yield:
0.94%
Consensus Rating:
Moderate Buy (0 Strong Buy Ratings, 6 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$145.67 (7.6% Upside)
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of Novo Nordisk A/S Stock

Pros

  • Novo Nordisk has consistently shown strong financial performance, with a return on equity of 91.70% and a net margin of 36.56% in the latest quarter.
  • The company's stock price has been steadily increasing, trading up 2.5% recently, reaching $142.41.
  • Novo Nordisk has a diverse product portfolio in the pharmaceutical industry, with a strong presence in various regions globally, providing stability and growth potential.

Cons

  • Novo Nordisk's stock has a relatively high price-to-earnings ratio of 49.09, which may indicate an overvaluation compared to industry peers.
  • The company's beta of 0.41 suggests lower volatility compared to the market average, potentially limiting short-term trading opportunities for investors seeking higher returns.
  • Novo Nordisk's debt-to-equity ratio of 0.17 may raise concerns about the company's leverage and financial risk management strategies.
UnitedHealth Group logo

#3 - UnitedHealth Group

NYSE:UNH - See Stock Forecast
Stock Price:
$573.19 (+$24.32)
Market Cap:
$505.17 billion
P/E Ratio:
35.0
Dividend Yield:
1.64%
Consensus Rating:
Buy (1 Strong Buy Ratings, 19 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$609.89 (6.4% Upside)
UnitedHealth Group Incorporated operates as a diversified health care company in the United States. The company operates through four segments: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx. The UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals; health care coverage, and health and well-being services to individuals age 50 and older addressing their needs; Medicaid plans, children's health insurance and health care programs; and health and dental benefits, and hospital and clinical services, as well as health care benefits products and services to state programs caring for the economically disadvantaged, medically underserved, and those without the benefit of employer-funded health care coverage. The Optum Health segment provides care delivery, care management, wellness and consumer engagement, and health financial services patients, consumers, care delivery systems, providers, employers, payers, and public-sector entities. The Optum Insight segment offers software and information products, advisory consulting arrangements, and managed services outsourcing contracts to hospital systems, physicians, health plans, governments, life sciences companies, and other organizations. The Optum Rx segment provides pharmacy care services and programs, including retail network contracting, home delivery, specialty and community health pharmacy services, infusion, and purchasing and clinical capabilities, as well as develops programs in the areas of step therapy, formulary management, drug adherence, and disease/drug therapy management. UnitedHealth Group Incorporated was founded in 1974 and is based in Minnetonka, Minnesota.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of UnitedHealth Group Stock

Pros

  • UnitedHealth Group has consistently increased its dividend over time, providing investors with a reliable income stream. The recent dividend increase from $1.88 to $2.10 per share showcases the company's commitment to rewarding shareholders.
  • Strong financial performance with a return on equity of 26.50% and a net margin of 4.05% indicates efficient management of resources and profitability, which can be attractive to investors seeking stable returns.
  • Positive analyst ratings and target price projections suggest a favorable outlook for the company's stock, with most analysts giving a buy or strong buy rating, indicating confidence in UnitedHealth Group's future growth potential.

Cons

  • The company's debt-to-equity ratio of 0.69 may raise concerns about its leverage levels, as a higher ratio indicates higher financial risk and potential vulnerability to economic downturns or interest rate fluctuations.
Johnson & Johnson logo

#4 - Johnson & Johnson

NYSE:JNJ - See Stock Forecast
Stock Price:
$156.58 (+$5.57)
Market Cap:
$363.43 billion
P/E Ratio:
9.8
Dividend Yield:
3.31%
Consensus Rating:
Hold (0 Strong Buy Ratings, 5 Buy Ratings, 8 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$174.07 (11.2% Upside)
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. Its MedTech segment provides Interventional Solutions, including electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; and neurovascular care that treats hemorrhagic and ischemic stroke. this segment also offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics, ear, nose, and throat procedures; contact lenses under the ACUVUE Brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of Johnson & Johnson Stock

Pros

  • Johnson & Johnson reported earnings per share of $2.71 for the quarter, beating analysts' estimates by $0.07. This indicates strong financial performance and potential for growth.
  • The company increased its dividend, with a quarterly dividend of $1.24 per share, representing a dividend yield of 3.38%. This can be attractive for income-seeking investors.
  • Institutional investors like SteelPeak Wealth LLC have been increasing their stake in Johnson & Johnson, indicating confidence in the company's future prospects.

Cons

  • Johnson & Johnson's 50-day moving average is $148.09, below the 200-day moving average of $153.97, indicating a short-term bearish trend in the stock price.
  • The company's PEG ratio of 2.43 may suggest that the stock is overvalued relative to its earnings growth potential, which could deter value-oriented investors.
  • While Johnson & Johnson has a strong dividend history, the dividend payout ratio of 30.92% may limit future dividend growth opportunities.
Merck & Co., Inc. logo

#5 - Merck & Co., Inc.

NYSE:MRK - See Stock Forecast
Stock Price:
$125.87 (+$0.43)
Market Cap:
$318.80 billion
P/E Ratio:
139.9
Dividend Yield:
2.40%
Consensus Rating:
Moderate Buy (1 Strong Buy Ratings, 8 Buy Ratings, 2 Hold Ratings, 1 Sell Ratings)
Consensus Price Target:
$135.36 (7.5% Upside)
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. The company serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians, wholesalers, government entities, veterinarians, distributors, animal producers, farmers, and pet owners. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates, which include patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan for the treatment of multiple solid tumors both as monotherapy and/or in combination with other treatments; and AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications. The company also has a collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of Merck & Co., Inc. Stock

Pros

  • Merck & Co., Inc. has shown consistent revenue growth over recent quarters, indicating a strong financial performance.
  • Merck's dividend yield of 2.32% provides investors with a steady income stream, offering a potential source of passive income.
  • Recent positive analyst ratings, including a "strong-buy" rating from Argus, suggest a favorable outlook for the company's stock.

Cons

  • Merck & Co., Inc.'s high price-to-earnings ratio of 147.73 may indicate an overvalued stock, potentially limiting future capital appreciation.
  • The company's debt-to-equity ratio of 0.77 suggests a moderate level of financial leverage, which could pose risks during economic downturns.
  • Some analysts have expressed concerns about Merck's growth potential, citing a price-to-earnings-growth ratio of 2.53 that may signal limited future earnings growth.
AbbVie logo

#6 - AbbVie

NYSE:ABBV - See Stock Forecast
Stock Price:
$175.29 (+$6.09)
Market Cap:
$309.54 billion
P/E Ratio:
52.0
Dividend Yield:
3.69%
Consensus Rating:
Moderate Buy (0 Strong Buy Ratings, 12 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$182.69 (4.2% Upside)
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of AbbVie Stock

Pros

  • AbbVie Inc. has a strong portfolio of pharmaceutical products, including Humira and Skyrizi, which have shown positive results in treating various diseases.
  • Recent developments in AbbVie's pipeline show promising potential for future growth and expansion in the pharmaceutical industry.
  • AbbVie's stock price has been relatively stable and has shown consistent growth over the past year, making it an attractive investment option.

Cons

  • There may be potential risks associated with AbbVie's heavy reliance on a few key pharmaceutical products, such as Humira, which could impact the company's revenue if faced with competition or patent expirations.
AstraZeneca logo

#7 - AstraZeneca

NASDAQ:AZN - See Stock Forecast
Stock Price:
$79.76 (+$1.17)
Market Cap:
$247.30 billion
P/E Ratio:
39.1
Dividend Yield:
2.47%
Consensus Rating:
Moderate Buy (2 Strong Buy Ratings, 5 Buy Ratings, 3 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$88.00 (10.3% Upside)
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of AstraZeneca Stock

Pros

  • AstraZeneca has shown consistent growth in revenue and earnings, with a positive EPS that has exceeded analysts' estimates.
  • The company has a strong return on equity of 30.42%, indicating efficient use of shareholder funds to generate profits.
  • Analysts have set a high price target for AstraZeneca, indicating positive sentiment and potential for stock price appreciation.

Cons

  • AstraZeneca's current stock price is trading near its 12-month high, which may indicate limited short-term upside potential.
  • The company's debt-to-equity ratio of 0.73 may raise concerns about its financial leverage and ability to manage debt obligations.
  • While the company has a strong PE ratio of 37.65, investors should be cautious of potential valuation risks associated with high PE ratios.
Novartis logo

#8 - Novartis

NYSE:NVS - See Stock Forecast
Stock Price:
$111.77 (+$1.24)
Market Cap:
$228.46 billion
P/E Ratio:
15.1
Dividend Yield:
2.20%
Consensus Rating:
Hold (0 Strong Buy Ratings, 2 Buy Ratings, 3 Hold Ratings, 1 Sell Ratings)
Consensus Price Target:
$118.13 (5.7% Upside)
Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of Novartis Stock

Pros

  • Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally, focusing on therapeutic areas such as cardiovascular, renal, metabolic, and immunology.
  • Novartis AG offers prescription medicines for patients and physicians, providing a wide range of healthcare solutions.

Cons

  • Novus Energy, Inc. (Novus) is a junior oil and gas company, not related to Novartis AG, which may cause confusion or misinformation for investors.
Thermo Fisher Scientific logo

#9 - Thermo Fisher Scientific

NYSE:TMO - See Stock Forecast
Stock Price:
$555.06 (-$0.36)
Market Cap:
$211.88 billion
P/E Ratio:
35.6
Dividend Yield:
0.28%
Consensus Rating:
Moderate Buy (0 Strong Buy Ratings, 12 Buy Ratings, 5 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$605.63 (9.1% Upside)
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, protein detection assays, and instruments; immunodiagnostics develops, manufactures and markets complete bloodtest systems to support the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. It offers products and services through a direct sales force, customer-service professionals, electronic commerce, and third-party distributors under Thermo Scientific; Applied Biosystems; Invitrogen; Fisher Scientific; Unity Lab Services; and Patheon and PPD. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of Thermo Fisher Scientific Stock

Pros

  • Thermo Fisher Scientific Inc. has a strong financial performance with a market cap of $206.17 billion, indicating stability and potential for growth.
  • The company consistently beats earnings estimates, as seen in the latest quarterly report where they surpassed the consensus EPS by $0.41, showcasing strong operational efficiency.
  • Analysts have a positive outlook on the stock, with a consensus price target of $607.94, indicating potential for price appreciation.

Cons

  • The stock price has experienced fluctuations, with a 50-day moving average price of $572.32 and a 200-day moving average price of $563.22, indicating potential volatility.
  • Insiders have been selling company stock, with recent transactions totaling 22,000 shares worth $12,532,780, which may raise concerns about insider sentiment.
  • While the company has a strong financial position, the current P/E ratio of 34.36 may be considered high by some investors, potentially impacting valuation.
Abbott Laboratories logo

#10 - Abbott Laboratories

NYSE:ABT - See Stock Forecast
Stock Price:
$104.71 (+$1.99)
Market Cap:
$182.16 billion
P/E Ratio:
32.6
Dividend Yield:
2.14%
Consensus Rating:
Moderate Buy (0 Strong Buy Ratings, 7 Buy Ratings, 3 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$120.18 (14.8% Upside)
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for laboratories. In addition, the company provides pediatric and adult nutritional products; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of Abbott Laboratories Stock

Pros

  • Abbott Laboratories has a strong return on equity of 20.18%, indicating efficient use of shareholder funds to generate profits.
  • The company has a healthy dividend payout ratio of 68.54%, providing investors with a steady income stream.
  • Abbott Laboratories has a diversified product portfolio across healthcare segments, reducing risk associated with dependence on a single product line.

Cons

  • Abbott Laboratories faces competition in the healthcare industry, which could impact its market share and profitability.
  • The company's stock price may be influenced by regulatory changes in the healthcare sector, leading to volatility in the stock value.
  • Market analysts have revised price targets for Abbott Laboratories, indicating uncertainty in future growth prospects.
Amgen logo

#11 - Amgen

NASDAQ:AMGN - See Stock Forecast
Stock Price:
$335.67 (+$2.53)
Market Cap:
$180.06 billion
P/E Ratio:
48.0
Dividend Yield:
2.73%
Consensus Rating:
Moderate Buy (0 Strong Buy Ratings, 11 Buy Ratings, 10 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$312.63 (-6.9% Downside)
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of Amgen Stock

Pros

  • Amgen's recent earnings report exceeded analysts' expectations, with a higher EPS of $3.96 compared to the consensus estimate of $3.76, indicating strong financial performance.
  • Multiple analyst upgrades and target price increases suggest positive sentiment towards Amgen's stock, potentially leading to price appreciation.
  • Amgen's current stock price of $310.88 on July 5th, 2024, is showing an upward trend, indicating potential growth opportunities.

Cons

  • Amgen's high debt-to-equity ratio of 11.96 may pose a risk in terms of financial leverage and potential constraints on future growth initiatives.
  • While Amgen's revenue was up 22.0% year-over-year, the company's net margin of 12.74% indicates relatively lower profitability compared to some competitors in the industry.
  • Despite recent positive analyst ratings, the stock's PE ratio of 44.41 and price-to-earnings-growth ratio of 2.79 may suggest that the stock is currently overvalued.
Pfizer logo

#12 - Pfizer

NYSE:PFE - See Stock Forecast
Stock Price:
$30.02 (+$0.52)
Market Cap:
$170.11 billion
Dividend Yield:
5.77%
Consensus Rating:
Hold (0 Strong Buy Ratings, 5 Buy Ratings, 8 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$34.50 (14.9% Upside)
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of Pfizer Stock

Pros

  • Pfizer Inc. has shown consistent growth in its earnings, with analysts raising their Q4 2025 earnings estimates for the company.
  • Positive analyst ratings and target price upgrades indicate confidence in Pfizer's future performance.
  • Pfizer's stock price has been relatively stable, providing a sense of security for investors.

Cons

  • Recent revenue decline compared to the same quarter last year may raise concerns about Pfizer's ability to sustain growth.
  • The company's negative net margin could indicate potential profitability challenges in the short term.
  • Pfizer's stock performance has been relatively flat, potentially limiting short-term gains for investors.
Intuitive Surgical logo

#13 - Intuitive Surgical

NASDAQ:ISRG - See Stock Forecast
Stock Price:
$426.23 (-$11.78)
Market Cap:
$151.18 billion
P/E Ratio:
76.9
Consensus Rating:
Moderate Buy (0 Strong Buy Ratings, 14 Buy Ratings, 5 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$423.37 (-0.7% Downside)
Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung. It also provides a suite of stapling, energy, and core instrumentation for its multi-port da Vinci surgical systems; progressive learning pathways to support the use of its technology; infrastructure of service and support specialists, a complement of services to its customers, including installation, repair, maintenance, 24/7 technical support, and proactive system health monitoring; and integrated digital capabilities providing connected offerings, streamlining performance for hospitals with program-enhancing insights. The company sells its products through direct sales organizations, such as capital and clinical sales teams. It has a collaboration agreement with FluoGuide A/S for head & neck cancer. The company was incorporated in 1995 and is headquartered in Sunnyvale, California.
Stryker logo

#14 - Stryker

NYSE:SYK - See Stock Forecast
Stock Price:
$334.64 (+$1.21)
Market Cap:
$127.48 billion
P/E Ratio:
38.2
Dividend Yield:
0.97%
Consensus Rating:
Moderate Buy (0 Strong Buy Ratings, 15 Buy Ratings, 4 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$372.05 (11.2% Upside)
Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries. This segment also offers spinal implant products comprising cervical and thoracolumbar systems that include fixation, minimally invasive and interbody systems used in spinal injury, complex spine and degenerative therapies. The MedSurg and Neurotechnology segment offers surgical equipment, and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, clinical communication and workflow solutions, and other medical device products that are used in various medical specialties, as well as patient and caregiver safety technologies. This segment also provides neurosurgical, neurovascular and craniomaxillofacial implant products, which include products used for minimally invasive endovascular procedures; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke; and craniomaxillofacial implant products, including cranial, maxillofacial, and chest wall devices, as well as dural substitutes and sealants. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Portage, Michigan.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of Stryker Stock

Pros

  • Stryker's stock price is currently trading at $344.72, showing stability and potential for growth in the future.
  • Stryker reported strong earnings results, beating analysts' estimates with an EPS of $2.50 for the quarter.
  • The company has a solid revenue growth rate of 9.7% year-over-year, indicating a healthy financial performance.

Cons

  • Stryker's price-to-earnings ratio of 39.35 is relatively high, suggesting the stock may be overvalued compared to industry peers.
  • The company's debt-to-equity ratio of 0.56 indicates a moderate level of debt, which could pose risks in a challenging economic environment.
  • Stryker's dividend yield of 0.96% may not be attractive to income-focused investors seeking higher dividend returns.
Sanofi logo

#15 - Sanofi

NASDAQ:SNY - See Stock Forecast
Stock Price:
$50.21 (+$0.16)
Market Cap:
$127.17 billion
P/E Ratio:
25.2
Dividend Yield:
2.95%
Consensus Rating:
Hold (0 Strong Buy Ratings, 1 Buy Ratings, 3 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$55.00 (9.5% Upside)
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.
Vertex Pharmaceuticals logo

#16 - Vertex Pharmaceuticals

NASDAQ:VRTX - See Stock Forecast
Stock Price:
$488.37 (-$0.61)
Market Cap:
$126.02 billion
P/E Ratio:
31.7
Consensus Rating:
Moderate Buy (0 Strong Buy Ratings, 17 Buy Ratings, 6 Hold Ratings, 3 Sell Ratings)
Consensus Price Target:
$452.57 (-7.3% Downside)
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
Elevance Health logo

#17 - Elevance Health

NYSE:ELV - See Stock Forecast
Stock Price:
$520.19 (-$32.95)
Market Cap:
$120.90 billion
P/E Ratio:
19.7
Dividend Yield:
1.23%
Consensus Rating:
Buy (1 Strong Buy Ratings, 14 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$612.79 (17.8% Upside)
Elevance Health, Inc., together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits. The company operates in the pharmacy services business; and markets and offers pharmacy services, including pharmacy benefit management, as well as home delivery and specialty pharmacies, claims adjudication, formulary management, pharmacy networks, rebate administration, a prescription drug database, and member services. In addition, it provides healthcare-related services and capabilities, including utilization management, behavioral health, integrated care delivery, palliative care, payment integrity services, subrogation services, and health and wellness programs, as well as services related to data management, information technology, and business operations. Further, the company is involved in the National Government Services business. The company provides its services under the Anthem Blue Cross and Blue Shield, Wellpoint, and Carelon brand names. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health, Inc. in June 2022. Elevance Health, Inc. was incorporated in 2001 and is headquartered in Indianapolis, Indiana.
Regeneron Pharmaceuticals logo

#18 - Regeneron Pharmaceuticals

NASDAQ:REGN - See Stock Forecast
Stock Price:
$1,085.62 (-$9.37)
Market Cap:
$119.62 billion
P/E Ratio:
32.1
Consensus Rating:
Moderate Buy (1 Strong Buy Ratings, 16 Buy Ratings, 4 Hold Ratings, 1 Sell Ratings)
Consensus Price Target:
$1,045.38 (-3.7% Downside)
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
Boston Scientific logo

#19 - Boston Scientific

NYSE:BSX - See Stock Forecast
Stock Price:
$77.42 (-$0.72)
Market Cap:
$113.58 billion
P/E Ratio:
65.1
Consensus Rating:
Moderate Buy (1 Strong Buy Ratings, 18 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$82.29 (6.3% Upside)
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a Left Atrial Appendage Closure Device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
Medtronic logo

#20 - Medtronic

NYSE:MDT - See Stock Forecast
Stock Price:
$81.29 (+$3.19)
Market Cap:
$104.24 billion
P/E Ratio:
29.6
Dividend Yield:
3.59%
Consensus Rating:
Hold (0 Strong Buy Ratings, 4 Buy Ratings, 6 Hold Ratings, 2 Sell Ratings)
Consensus Price Target:
$90.82 (11.7% Upside)
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and products. The company's Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases, as well as products in the fields of minimally invasive gastrointestinal and hepatologic diagnostics and therapies, patient monitoring, airway management and ventilation therapies, and renal disease. Its Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The company's Diabetes Operating Unit segment offers insulin pumps and consumables, continuous glucose monitoring systems, smart insulin pen systems, and consumables and supplies. The company was founded in 1949 and is headquartered in Dublin, Ireland.
The Cigna Group logo

#21 - The Cigna Group

NYSE:CI - See Stock Forecast
Stock Price:
$344.75 (+$5.04)
Market Cap:
$97.93 billion
P/E Ratio:
28.3
Dividend Yield:
1.69%
Consensus Rating:
Buy (2 Strong Buy Ratings, 13 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$376.20 (9.1% Upside)
The Cigna Group, together with its subsidiaries, provides insurance and related products and services in the United States. Its Evernorth Health Services segment provides a range of coordinated and point solution health services, including pharmacy benefits, home delivery pharmacy, specialty pharmacy, distribution, and care delivery and management solutions to health plans, employers, government organizations, and health care providers. The company's Cigna Healthcare segment offers medical, pharmacy, behavioral health, dental, and other products and services for insured and self-insured customers; Medicare Advantage, Medicare Supplement, and Medicare Part D plans for seniors, as well as individual health insurance plans; and health care coverage in its international markets, as well as health care benefits for mobile individuals and employees of multinational organizations. In addition, it offers permanent insurance contracts sold to corporations to provide coverage on the lives of certain employees for financing employer-paid future benefit obligations. The company distributes its products and services through insurance brokers and consultants; directly to employers, unions and other groups, or individuals; and private and public exchanges. The company was formerly known as Cigna Corporation and changed its name to The Cigna Group in February 2023. The Cigna Group was founded in 1792 and is headquartered in Bloomfield, Connecticut.
Gilead Sciences logo

#22 - Gilead Sciences

NASDAQ:GILD - See Stock Forecast
Stock Price:
$73.30 (+$1.66)
Market Cap:
$91.32 billion
P/E Ratio:
203.6
Dividend Yield:
4.35%
Consensus Rating:
Hold (0 Strong Buy Ratings, 7 Buy Ratings, 12 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$84.00 (14.6% Upside)
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.
Bristol-Myers Squibb logo

#23 - Bristol-Myers Squibb

NYSE:BMY - See Stock Forecast
Stock Price:
$43.17 (+$1.96)
Market Cap:
$87.50 billion
Dividend Yield:
5.93%
Consensus Rating:
Hold (0 Strong Buy Ratings, 3 Buy Ratings, 13 Hold Ratings, 1 Sell Ratings)
Consensus Price Target:
$59.07 (36.8% Upside)
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.
HCA Healthcare logo

#24 - HCA Healthcare

NYSE:HCA - See Stock Forecast
Stock Price:
$323.01 (+$4.10)
Market Cap:
$84.60 billion
P/E Ratio:
16.1
Dividend Yield:
0.83%
Consensus Rating:
Moderate Buy (1 Strong Buy Ratings, 13 Buy Ratings, 4 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$327.06 (1.3% Upside)
HCA Healthcare, Inc., through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy. The company also operates outpatient health care facilities consisting of freestanding ambulatory surgery centers, freestanding emergency care facilities, urgent care facilities, walk-in clinics, diagnostic and imaging centers, rehabilitation and physical therapy centers, radiation and oncology therapy centers, physician practices, and various other facilities. In addition, it operates behavioral hospitals, which provide therapeutic programs comprising child, adolescent and adult psychiatric care, adolescent and adult alcohol, drug abuse treatment, and counseling services. The company was formerly known as HCA Holdings, Inc. HCA Healthcare, Inc. was founded in 1968 and is headquartered in Nashville, Tennessee.
Zoetis logo

#25 - Zoetis

NYSE:ZTS - See Stock Forecast
Stock Price:
$182.06 (-$0.85)
Market Cap:
$83.07 billion
P/E Ratio:
35.1
Dividend Yield:
0.97%
Consensus Rating:
Buy (0 Strong Buy Ratings, 7 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$211.75 (16.3% Upside)
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, other pharmaceutical, anti-infectives, animal health diagnostics, and medicated feed additives. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaboration Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was founded in 1952 and is headquartered in Parsippany, New Jersey.
GSK logo

#26 - GSK

NYSE:GSK - See Stock Forecast
Stock Price:
$39.83 (+$0.93)
Market Cap:
$82.55 billion
P/E Ratio:
14.4
Dividend Yield:
3.90%
Consensus Rating:
Moderate Buy (2 Strong Buy Ratings, 2 Buy Ratings, 3 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$50.00 (25.5% Upside)
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.
McKesson logo

#27 - McKesson

NYSE:MCK - See Stock Forecast
Stock Price:
$582.34 (-$1.61)
Market Cap:
$75.67 billion
P/E Ratio:
26.0
Dividend Yield:
0.43%
Consensus Rating:
Moderate Buy (0 Strong Buy Ratings, 14 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$596.00 (2.3% Upside)
McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products. This segment also provides practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices; and consulting, outsourcing, technological, and other services, as well as sells financial, operational, and clinical solutions to pharmacies. The RxTS segment serves biopharma and life sciences partners and patients to address medication challenges for patients by working across healthcare; connects patients, pharmacies, providers, pharmacy benefit managers, health plans, and biopharma companies to deliver innovative solutions to help people get the medicine needed to live healthier lives; and provides prescription price transparency, benefit insight, dispensing support, third-party logistics, and wholesale distribution support services. The Medical-Surgical Solutions segment provides medical-surgical supply distribution, logistics, and other services to healthcare providers, including physician offices, surgery centers, nursing homes, hospital reference labs, and home health care agencies. The International segment offers distribution and services to wholesale, institutional, and retail customers in Europe and Canada. McKesson Corporation was founded in 1833 and is headquartered in Irving, Texas.
Aetna logo

#28 - Aetna

NYSE:AET - See Stock Forecast
Stock Price:
$212.70
Market Cap:
$69.64 billion
P/E Ratio:
21.6
Dividend Yield:
0.94%
Consensus Rating:
N/A (0 Strong Buy Ratings, 0 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
N/A
Aetna Inc. operates as a health care benefits company in the United States. It operates through three segments: Health Care, Group Insurance, and Large Case Pensions. The Health Care segment offers medical, pharmacy benefit management service, dental, behavioral health, and vision plans on an insured and employer-funded basis. It also provides point-of-service, preferred provider organization, health maintenance organization, and indemnity benefit plans, as well as health savings accounts and consumer-directed health plans. In addition, this segment offers Medicare and Medicaid products and services, as well as other medical products, such as medical management and data analytics services, medical stop loss insurance, workers' compensation administrative services, and products that provide access to its provider networks in select geographies. The Group Insurance segment offers life insurance products, including group term life insurance, voluntary spouse and dependent term life insurance, group universal life insurance, and accidental death and dismemberment insurance; disability insurance products; and long-term care insurance products, which provide the benefits to cover the cost of care in private home settings, adult day care, assisted living, or nursing facilities. The Large Case Pensions segment manages various retirement products comprising pension and annuity products primarily for tax-qualified pension plans. The company provides its products and services to employer groups, individuals, college students, part-time and hourly workers, health plans, health care providers, governmental units, government-sponsored plans, labor groups, and expatriates. Aetna Inc. was founded in 1853 and is based in Hartford, Connecticut.
Becton, Dickinson and Company logo

#29 - Becton, Dickinson and Company

NYSE:BDX - See Stock Forecast
Stock Price:
$234.08 (+$3.38)
Market Cap:
$67.65 billion
P/E Ratio:
51.6
Dividend Yield:
1.66%
Consensus Rating:
Moderate Buy (0 Strong Buy Ratings, 6 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$280.14 (19.7% Upside)
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.
Allergan logo

#30 - Allergan

NYSE:AGN - See Stock Forecast
Stock Price:
$193.02
Market Cap:
$63.50 billion
Dividend Yield:
1.53%
Consensus Rating:
N/A (0 Strong Buy Ratings, 0 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
N/A
Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. The company operates in three segments: US Specialized Therapeutics, US General Medicine, and International. It offers a portfolio of products in various therapeutic areas, including medical aesthetics and dermatology, eye care, neuroscience, urology, gastrointestinal, women's health, and anti-infective therapeutic products. The company also offers breast implants and tissue expanders; and RM-131 (relamorelin), a peptide ghrelin agonist for the treatment of diabetic gastroparesis. In addition, it develops medical and cosmetic treatments; therapies for non-alcoholic steatohepatitis and other liver diseases; inhibitor for the treatment of psoriasis and other autoimmune disorders; atopic dermatitis drug candidate; peri-ocular rings for extended drug delivery and reducing elevated intraocular pressure in glaucoma patients; and treatments for neurodegenerative disorders, including Alzheimer's disease. Further, the company develops RST-001, a novel gene therapy for the treatment of retinitis pigmentosa; small molecule therapeutics for inflammatory and fibrotic diseases; topical medicines for fat reduction; and delivery system and botulinum toxin-based prescription products. It has collaboration, option, and license agreement with Lyndra, Inc.; and strategic alliance and option agreement with Editas Medicine, Inc. Allergan plc also has licensing agreements with Assembly Biosciences, Inc.; MedImmune; and Heptares Therapeutics, Ltd. The company was formerly known as Actavis plc and changed its name to Allergan plc in June 2015. Allergan plc was founded in 1983 and is headquartered in Dublin, Ireland.
Shire logo

#31 - Shire

NASDAQ:SHPG - See Stock Forecast
Stock Price:
$179.20
Market Cap:
$54.71 billion
P/E Ratio:
11.8
Dividend Yield:
0.19%
Consensus Rating:
N/A (0 Strong Buy Ratings, 0 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
N/A
Shire plc, a biotechnology company, researches, develops, licenses, manufactures, markets, distributes, and sells medicines for rare diseases and other specialized conditions worldwide. The company offers products in therapeutic areas, including hematology, genetic diseases, neuroscience, immunology, internal medicine, ophthalmology, and oncology. Its marketed products include ADVATE, ADYNOVATE/ADYNOVI, and OBIZUR for the treatment of hemophilia A; RIXUBIS to treat hemophilia B; VONVENDI for the treatment of von willebrand disease; FEIBA to treat hemophilia A and B patients with inhibitors; ELAPRASE to treat hunter syndrome; REPLAGAL for fabry disease; and VPRIV to treat type 1 Gaucher disease. The company's marketed products also comprise VYVANSE/VENVANSE/ELVANSE/TYVENSE/VUXEN/ADUVANZ for the treatment of attention deficit/hyperactivity disorder (ADHD) and binge eating disorder; ADDERALL XR and MYDAYIS to treat ADHD; GAMMAGARD LIQUID/KIOVIG, GAMMAGARD S/D, HYQVIA, and CUVITRU for the treatment of primary immunodeficiency; and FLEXBUMIN to treat hypovolemia and hypoalbuminemia. In addition, its marketed products consists of CINRYZE and FIRAZYR for the treatment of hereditary angioedema; FOSRENOL to treat hyperphosphatemia; LIALDA/MEZAVANT and PENTASA for ulcerative colitis; GATTEX/REVESTIVE for the treatment of short bowel syndrome; NATPARA for the control of hypocalcemia in patients with hypoparathyroidism; ONCASPAR to treat acute lymphoblastic leukemia; ONYVIDE for metastatic adenocarcinoma of the pancreas; and XIIDRA for the treatment of dry eye disease. The company markets its products through wholesalers, distributors, and pharmacies. It has collaborative and other licensing arrangements with Rani Therapeutics LLC; Parion Sciences Inc.; Pfizer Inc.; Precision BioSciences Inc.; Symphogen; and Ipsen Bioscience Inc., as well as a preclinical research collaboration agreement with NanoMedSyn. The company was founded in 1986 and is headquartered in Dublin, Ireland.
Edwards Lifesciences logo

#32 - Edwards Lifesciences

NYSE:EW - See Stock Forecast
Stock Price:
$87.32 (-$0.42)
Market Cap:
$52.62 billion
P/E Ratio:
37.6
Consensus Rating:
Moderate Buy (0 Strong Buy Ratings, 14 Buy Ratings, 5 Hold Ratings, 1 Sell Ratings)
Consensus Price Target:
$96.76 (10.8% Upside)
Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; INSPIRIS RESILLA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valves conduit for complex combined procedures; and MITRIS RESILIA valve. In addition, it offers critical care solutions, including hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings under the FloTrac, Acumen IQ sensors, ClearSight, Acumen IQ cuffs, and ForeSight names; HemoSphere, a monitoring platform that displays physiological information; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Express Scripts logo

#33 - Express Scripts

NASDAQ:ESRX - See Stock Forecast
Stock Price:
$92.33
Market Cap:
$52.06 billion
P/E Ratio:
13.0
Consensus Rating:
N/A (0 Strong Buy Ratings, 0 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
N/A
Express Scripts Holding Company operates as a pharmacy benefit management (PBM) company in the United States and Canada. The company's PBM segment offers clinical solutions; and specialized pharmacy care, home delivery and specialty pharmacy, retail network pharmacy administration, benefit design consultation, drug utilization review, drug formulary management, public exchange, administration of group purchasing organization, and digital consumer health and drug information services. This segment also provides Medicare, Medicaid, and health insurance marketplace products; Express Scripts SafeGuardRx, a suite of solutions targeting the therapy classes that pose clinical challenges and budgetary threat to its clients; and Inside Rx, a program that provide affordable access to medication for uninsured and underinsured individuals. Its Other Business Operations segment distributes specialty pharmaceuticals and medical supplies, including injectable and infusible pharmaceuticals and medications to treat specialty and rare/orphan diseases. This segment also provides medical benefit management solutions for radiology, cardiology, musculoskeletal disorders, sleep disorders, post-acute care, genetic lab, specialty pharmacy, and medical oncology. The company serves managed care organizations, health insurers, third-party administrators, employers, union-sponsored benefit plans, workers' compensation plans, government health programs, providers, clinics, hospitals, and others. As of December 31, 2017, it operated 4 automated dispensing home delivery pharmacies; 1 non-automated dispensing home delivery pharmacy; 7 non-dispensing order processing centers; 5 patient contact centers; 9 specialty home delivery pharmacies; and 34 specialty branch pharmacies. The company was formerly known as Aristotle Holding, Inc. and changed its name to Express Scripts Holding Company in April 2012. Express Scripts Holding Company was founded in 1986 and is headquartered in Saint Louis, Missouri.
Humana logo

#34 - Humana

NYSE:HUM - See Stock Forecast
Stock Price:
$401.88 (+$6.28)
Market Cap:
$48.43 billion
P/E Ratio:
25.0
Dividend Yield:
0.92%
Consensus Rating:
Hold (0 Strong Buy Ratings, 9 Buy Ratings, 13 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$402.05 (0.0% Upside)
Humana Inc., together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits. In addition, the company provides commercial fully-insured medical and specialty health insurance benefits comprising dental, vision, life insurance, and other supplemental health benefits, as well as administrative services only products to individuals and employer groups; military services, such as TRICARE T2017 East Region contract; and engages in the operations of pharmacy benefit manager business. Further, it operates pharmacies and senior focused primary care centers; and offers home solutions services, such as home health, hospice, and other services to its health plan members, as well as to third parties. The company sells its products through employers and employees, independent brokers and agents, sales representatives, and digital insurance agencies. The company was formerly known as Extendicare Inc. and changed its name to Humana Inc. in April 1974. Humana Inc. was founded in 1961 and is headquartered in Louisville, Kentucky.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of Humana Stock

Pros

  • Humana's strong quarterly earnings results, beating consensus estimates, and showing a positive trend in revenue growth.
  • Consistent dividend payments with a dividend yield of 1.01%, providing investors with a steady income stream.
  • Positive analyst ratings with a majority of analysts giving a "buy" or "outperform" rating, indicating confidence in the company's performance.

Cons

  • Analysts lowering price targets on Humana stock, signaling potential concerns about future growth prospects.
  • Neutral ratings from some analysts, suggesting uncertainty in the company's future performance.
  • Market volatility and regulatory changes in the healthcare sector could impact Humana's business operations and financial results.
Moderna logo

#35 - Moderna

NASDAQ:MRNA - See Stock Forecast
Stock Price:
$124.06 (-$1.08)
Market Cap:
$47.54 billion
Consensus Rating:
Hold (0 Strong Buy Ratings, 7 Buy Ratings, 9 Hold Ratings, 2 Sell Ratings)
Consensus Price Target:
$134.02 (8.0% Upside)
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of Moderna Stock

Pros

  • Moderna's innovative approach to mRNA therapeutics and vaccines could lead to groundbreaking treatments for various diseases, potentially driving significant revenue growth.
  • Recent insider trading activity, such as President Stephen Hoge selling shares, may indicate confidence in the company's future prospects.
  • Moderna's strong financial position with a quick ratio of 3.91 and current ratio of 4.03 suggests stability and ability to meet short-term obligations.

Cons

  • Moderna's negative net margin of 115.82% and negative return on equity of 20.10% indicate financial challenges and potential risks for investors.
  • The company's quarterly revenue decline of 91.0% year-over-year raises concerns about its ability to sustain growth and profitability.
  • Moderna's high beta of 1.66 suggests higher volatility compared to the market average, which may lead to increased investment risk.
DexCom logo

#36 - DexCom

NASDAQ:DXCM - See Stock Forecast
Stock Price:
$114.61 (-$1.45)
Market Cap:
$45.58 billion
P/E Ratio:
73.9
Consensus Rating:
Moderate Buy (1 Strong Buy Ratings, 11 Buy Ratings, 3 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$139.33 (21.6% Upside)
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of DexCom Stock

Pros

  • DexCom's recent positive earnings report, beating the consensus estimate by $0.05 per share, indicates strong financial performance.
  • The company's focus on continuous glucose monitoring (CGM) systems for diabetes management aligns with the growing demand for healthcare technology solutions.
  • With a consensus target price of $140.94, there is potential for stock price appreciation, making it an attractive investment opportunity.

Cons

  • The stock's price-to-earnings ratio of 75.61 may indicate an overvalued position, potentially leading to limited upside for investors.
  • Despite positive ratings from analysts, the stock's beta of 1.22 suggests higher volatility compared to the market average, posing risk for investors.
  • Insider selling activity, with company insiders offloading significant shares in recent months, could signal lack of confidence in future growth prospects.
Cencora logo

#37 - Cencora

NYSE:COR - See Stock Forecast
Stock Price:
$225.14 (-$0.24)
Market Cap:
$44.90 billion
P/E Ratio:
24.6
Dividend Yield:
0.92%
Consensus Rating:
Moderate Buy (0 Strong Buy Ratings, 6 Buy Ratings, 3 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$238.78 (6.1% Upside)
Cencora, Inc. sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers. This segment also distributes plasma and other blood products, injectable pharmaceuticals, vaccines, and other specialty products; and provides other services to physicians who specialize in various disease states, such as oncology, as well as to other healthcare providers, including hospitals and dialysis clinics. Its International Healthcare Solutions segment offers international pharmaceutical wholesale and related service, and global commercialization services; distributes pharmaceuticals, other healthcare products, and related services to pharmacies, doctors, health centers, and hospitals primarily in Europe; and provides specialty transportation and logistics services for the biopharmaceutical industry. The company was formerly known as AmerisourceBergen Corporation and changed its name to Cencora, Inc. in August 2023. Cencora, Inc. was incorporated in 2001 and is headquartered in Conshohocken, Pennsylvania.
Alcon logo

#38 - Alcon

NYSE:ALC - See Stock Forecast
Stock Price:
$90.01 (-$0.25)
Market Cap:
$44.40 billion
P/E Ratio:
42.7
Consensus Rating:
Moderate Buy (0 Strong Buy Ratings, 13 Buy Ratings, 2 Hold Ratings, 1 Sell Ratings)
Consensus Price Target:
$96.71 (7.4% Upside)
Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products for eye care professionals and their patients worldwide. The company's Surgical segment offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for surgical procedures. Its cataract products include Centurion vision system, LenSx laser system, ARGOS biometer, LuxOR surgical ophthalmic microscope, SMARTCATARACT health platform, NGENUITY 3D visualization system, Verion reference unit and Verion digital marker, and ORA system for intra-operative measurements; custom pak surgical procedure packs; vitreoretinal products comprising constellation vision systems, procedure packs, lasers and hand-held microsurgical instruments, and grieshaber and MIVS instruments, as well as scissors, forceps and micro-instruments, medical grade vitreous tamponades, and Hypervit vitrectomy probes; refractive surgery products, including WaveLight lasers and Contoura Vision used for LASIK treatment; EX-PRESS glaucoma filtration device; and implantable products, including AcrySof IQ products, such as monofocal IOLs and advanced technology IOLs for the correction of presbyopia and astigmatism at the time of cataract surgery. Its Vision Care segment provides daily disposable, reusable, and color-enhancing contact lenses; ocular health products, such as dry eye, glaucoma, contact lens care, and ocular allergies; and ocular vitamins and redness relievers. The company was formerly known as Alcon Universal S.A. and changed its name to Alcon Inc. in December 2001. Alcon Inc. was founded in 1945 and is headquartered in Geneva, Switzerland.
Takeda Pharmaceutical logo

#39 - Takeda Pharmaceutical

NYSE:TAK - See Stock Forecast
Stock Price:
$13.70 (+$0.40)
Market Cap:
$43.36 billion
P/E Ratio:
24.9
Dividend Yield:
3.56%
Consensus Rating:
N/A (0 Strong Buy Ratings, 0 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$14.00 (2.2% Upside)
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.
Seagen logo

#40 - Seagen

NASDAQ:SGEN - See Stock Forecast
Stock Price:
$228.74
Market Cap:
$42.93 billion
Consensus Rating:
Hold (0 Strong Buy Ratings, 0 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$229.00 (0.1% Upside)
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. It offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of adult patients with advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. The company also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-TGT and SEA-CD70 for various cancer diseases. It has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and RemeGen, Co. Ltd. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington. As of December 14, 2023, Seagen Inc. operates as a subsidiary of Pfizer Inc.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of Seagen Stock

Pros

  • Seagen Inc. has shown a positive Month-to-Month Change Percentage in short interest, indicating potential stability.
  • The institutional ownership percentage is high at 91.8%, suggesting confidence from large investors.
  • Seagen Inc. has a strong Fifty-Two Week Performance, showcasing consistent growth over the past year.

Cons

  • Seagen Inc. has a relatively high Days to Cover ratio of 4.1, which may indicate a longer time for short sellers to close their positions.
  • There has been a slight decrease in Shares Shorted from the previous month, which could suggest a shift in market sentiment.
  • The Short Percentage of Float is 0, which may indicate limited short-term trading opportunities.
I’m giving you the name of this investment for free (Ad)

What people don’t know is that Roivant is capitalizing on a wealth secret that goes back over a century. There are a few other public companies who are as well. Only you don’t know it… because it’s not something they openly talk about. That’s why I made this presentation. I want to expose you to a wealth-building secret that you deserve to benefit from.

You deserve to see this for your own good.
IQVIA logo

#41 - IQVIA

NYSE:IQV - See Stock Forecast
Stock Price:
$230.29 (-$2.68)
Market Cap:
$41.96 billion
P/E Ratio:
31.5
Consensus Rating:
Moderate Buy (0 Strong Buy Ratings, 13 Buy Ratings, 3 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$255.73 (11.0% Upside)
IQVIA Holdings Inc. engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a collaboration with argenx SE. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. The company is headquartered in Durham, North Carolina.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of IQVIA Stock

Pros

  • IQVIA Holdings Inc. provides advanced analytics, technology solutions, and clinical research services to the life sciences industry globally, offering a diverse range of services that cater to a growing market demand.
  • Recent developments in the company's Technology & Analytics Solutions segment have shown promising growth potential, indicating a strong position in the market.
  • IQVIA Holdings Inc. has demonstrated consistent innovation and adaptation to industry trends, ensuring relevance and competitiveness in the market.

Cons

  • While IQVIA Holdings Inc. has shown growth potential, there may be risks associated with market volatility and regulatory changes that could impact the company's performance.
  • Competition within the life sciences industry is intense, and IQVIA Holdings Inc. may face challenges in maintaining its market position against other established players.
  • Investing in IQVIA Holdings Inc. requires a thorough understanding of the healthcare and life sciences sector, as well as the ability to navigate complex regulatory environments that could affect the company's operations.
IDEXX Laboratories logo

#42 - IDEXX Laboratories

NASDAQ:IDXX - See Stock Forecast
Stock Price:
$496.47 (-$3.05)
Market Cap:
$41.00 billion
P/E Ratio:
48.1
Consensus Rating:
Moderate Buy (0 Strong Buy Ratings, 6 Buy Ratings, 3 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$586.63 (18.2% Upside)
IDEXX Laboratories, Inc. develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. It also provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory diagnostic instruments, and services for biomedical research community. In addition, the company offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; point-of-care electrolytes and blood gas analyzers; in-clinic chemistry, blood and urine chemistry, hematology, immunoassay, urinalysis, and coagulation analyzers; and SNAP rapid assays test kits. Further, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; and veterinary software and services for independent veterinary clinics and corporate groups. Additionally, the company offers human medical point-of-care products and laboratory diagnostics services. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.
Haleon logo

#43 - Haleon

NYSE:HLN - See Stock Forecast
Stock Price:
$8.92 (+$0.17)
Market Cap:
$40.73 billion
P/E Ratio:
29.7
Dividend Yield:
2.40%
Consensus Rating:
Moderate Buy (0 Strong Buy Ratings, 4 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
N/A
Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands. It also offers various over-the-counter products comprising nasal drops, and cold, flu, and allergy relief products under Otrivine, Theraflu, and Flonase brands for respiratory issues; anti-inflammatory and pain relief products under Voltaren, Panadol, and Advil brands; and antacids and antihistamine products under TUMS, ENO, and Fenistil brands for digestive health and other issues. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was founded in 1715 and is headquartered in Weybridge, the United Kingdom.
Alexion Pharmaceuticals logo

#44 - Alexion Pharmaceuticals

NASDAQ:ALXN - See Stock Forecast
Stock Price:
$182.50
Market Cap:
$40.34 billion
P/E Ratio:
59.6
Consensus Rating:
N/A (0 Strong Buy Ratings, 0 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
N/A
Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products. The company offers ULTOMIRIS for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS); and SOLIRIS for the treatment of PNH, aHUS, generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). It also provides Strensiq for patients with hypophosphatasia; Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency; and Andexxa, a reversal agent for patients treated with rivaroxaban or apixaban. In addition, the company is developing ALXN1210 (Intravenous) that is in Phase III clinical trials for the treatment of gMG, NMOSD, ALS, COVID-19, and HSCT-TMA; ALXN1210 (Subcutaneous), which is in Phase III clinical trials for PNH and aHUS; ALXN1820 that is in Phase I clinical trial, a therapeutic antagonist of properdin; and ALXN1720, which is in Phase I clinical trial for the treatment of disease states involving dysregulated terminal complement activity. Further, it is developing ALXN1840 that is in Phase III clinical trials for the treatment of Wilson disease; ALXN1830, which are in Phase I clinical trials for neonatal Fc receptor; ALXN2040 and ALXN2050 to treat diseases associated with dysregulation of the complement alternative pathway; ALXN1850, an enzyme replacement therapy; ALXN2060 for treating transthyretin amyloidosis; and ALXN2075 for treatment of relapsed/refractory chronic lymphocytic leukemia. The company serves distributors, pharmacies, hospital, hospital buying groups, and other healthcare providers in the United States and internationally. Alexion Pharmaceuticals, Inc. has collaboration and license agreement with Halozyme Therapeutics, Inc.; and agreements with Dicerna Pharmaceuticals, Inc., Zealand Pharma A/S, Caelum Biosciences, Inc., Stealth BioTherapeutics Corp., and Affibody AB. The company was founded in 1992 and is headquartered in Boston, Massachusetts.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of Alexion Pharmaceuticals Stock

Pros

  • No recent pro reasons available for Alexion Pharmaceuticals, Inc.

Cons

  • No recent con reasons available for Alexion Pharmaceuticals, Inc.
GE HealthCare Technologies logo

#45 - GE HealthCare Technologies

NASDAQ:GEHC - See Stock Forecast
Stock Price:
$82.47 (-$0.17)
Market Cap:
$37.64 billion
P/E Ratio:
24.1
Dividend Yield:
0.15%
Consensus Rating:
Moderate Buy (0 Strong Buy Ratings, 6 Buy Ratings, 5 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$94.09 (14.1% Upside)
GE HealthCare Technologies Inc. engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging segment offers molecular imaging, computed tomography (CT) scanning, magnetic resonance (MR) imaging, image-guided therapy, X-ray systems, and women's health products. The Ultrasound segment provides medical devices and solutions for screening, diagnosis, treatment, and monitoring of certain diseases in clinical areas, such as radiology and primary care, women's health, cardiovascular, and point of care and handheld ultrasound solutions, as well as surgical visualization and guidance products. The Patient Care Solutions segment provides medical devices, consumables, services, and digital solutions. Its portfolio includes patient monitoring solutions, anesthesia delivery and respiratory care products, electrocardiogram solutions, maternal infant care products, and consumables and services. The Pharmaceutical Diagnostics supplies diagnostic agents, including CT, angiography and X-ray, MR, single-photon emission computed tomography, positron emission tomography, and ultrasound to the radiology and nuclear medicine industry. The segment also provides contrast media pharmaceuticals that are administered to a patient prior to certain diagnostic scans to increase the visibility of tissues or structures during imaging exams; and molecular imaging agents or radiopharmaceuticals, which are molecular tracers labeled with radioisotopes. It has an AI collaboration with Mass General Brigham. The company was formerly known as GE Healthcare Holding LLC and changed its name to GE HealthCare Technologies Inc. in December 2022. The company was incorporated in 2022 and is headquartered in Chicago, Illinois.
Centene logo

#46 - Centene

NYSE:CNC - See Stock Forecast
Stock Price:
$67.80 (-$1.31)
Market Cap:
$36.18 billion
P/E Ratio:
13.5
Consensus Rating:
Hold (0 Strong Buy Ratings, 6 Buy Ratings, 8 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$86.23 (27.2% Upside)
Centene Corporation operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, commercial organizations, and military families in the United States. The company operates through Medicaid, Medicare, Commercial, and Other segments. The Medicaid segment offers health plan coverage, including medicaid expansion, aged, blind, disabled, children's health insurance program, foster care, medicare-medicaid plans, long-term services and support. This segment also provides healthcare products. The Medicare segment offers special needs and medicare supplement, and prescription drug plans. The Commercial segment provides health insurance marketplace product for individual, small, and large group commercials. It also operates clinical healthcare and pharmacies, as well as offers dental services. In addition, the company engages in the government contracts business under the TRICARE program and other healthcare related government contracts. It provides services through primary and specialty care physicians, hospitals, and ancillary providers. Centene Corporation was founded in 1984 and is headquartered in Saint Louis, Missouri.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of Centene Stock

Pros

  • Centene reported strong earnings per share (EPS) of $2.26 for the quarter, beating the consensus estimate by $0.17, indicating solid financial performance.
  • The company had revenue of $40.41 billion for the quarter, surpassing analysts' expectations, showcasing robust revenue growth.
  • Insider buying activity: Point72 Hong Kong Ltd acquired 131,459 shares of Centene Co., indicating confidence in the company's future prospects.

Cons

  • Centene's net margin of 1.76% may indicate lower profitability compared to some other companies in the industry, posing a risk for investors.
  • The company's return on equity of 14.19% is relatively moderate, suggesting potential limitations in generating returns for shareholders.
  • High institutional ownership: 93.63% of the stock is currently owned by institutional investors, which could lead to limited influence for individual investors.
Biogen logo

#47 - Biogen

NASDAQ:BIIB - See Stock Forecast
Stock Price:
$228.33 (+$3.31)
Market Cap:
$33.24 billion
P/E Ratio:
28.5
Consensus Rating:
Moderate Buy (0 Strong Buy Ratings, 17 Buy Ratings, 9 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$286.00 (25.3% Upside)
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Alnylam Pharmaceuticals logo

#48 - Alnylam Pharmaceuticals

NASDAQ:ALNY - See Stock Forecast
Stock Price:
$240.02 (-$9.81)
Market Cap:
$30.36 billion
Consensus Rating:
Moderate Buy (0 Strong Buy Ratings, 16 Buy Ratings, 8 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$253.55 (5.6% Upside)
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
ResMed logo

#49 - ResMed

NYSE:RMD - See Stock Forecast
Stock Price:
$205.97 (-$0.83)
Market Cap:
$30.26 billion
P/E Ratio:
31.6
Dividend Yield:
0.94%
Consensus Rating:
Moderate Buy (0 Strong Buy Ratings, 6 Buy Ratings, 5 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$202.80 (-1.5% Downside)
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. It operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME) to streamline their sleep programs; connectivity module and propeller solutions; and Propeller portal. It offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice organizations, as well as related accountable care organizations; HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies; and MEDIFOX DAN's software solutions. The company markets its products to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force. The company was founded in 1989 and is headquartered in San Diego, California.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of ResMed Stock

Pros

  • ResMed's recent increase in target price by KeyCorp and Royal Bank of Canada indicates positive sentiment from analysts, potentially leading to stock price appreciation.
  • ResMed's consistent dividend payments, with a recent quarterly dividend of $0.48 per share, providing investors with a steady income stream.
  • Insiders owning 1.21% of the company's stock can signal confidence in the company's future performance, aligning their interests with shareholders.

Cons

  • The recent downgrade by Oppenheimer and Citigroup from "outperform" and "buy" ratings to "market perform" and "neutral" ratings respectively may indicate potential challenges or concerns in the company's performance.
  • ResMed's stock price volatility, influenced by market conditions and industry competition, may lead to fluctuations in investment returns.
  • While insider ownership can be positive, high levels of insider selling, such as the recent 31,151 shares sold, could raise questions about insider confidence or future prospects.
Cerner logo

#50 - Cerner

NASDAQ:CERN - See Stock Forecast
Stock Price:
$94.92
Market Cap:
$27.92 billion
P/E Ratio:
47.7
Dividend Yield:
1.14%
Consensus Rating:
N/A (0 Strong Buy Ratings, 0 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
N/A
Cerner Corporation, together with its subsidiaries, provides health care information technology solutions and tech-enabled services in the United States and internationally. It offers Cerner Millennium architecture, a person-centric computing framework, which includes clinical, financial, and management information systems that allow providers to access an individual's electronic health record (EHR) at the point of care, and organizes and delivers information for physicians, nurses, laboratory technicians, pharmacists, front- and back-office professionals, and consumers. The company also provides HealtheIntent platform, a cloud-based platform to aggregate, transform, and reconcile data across the continuum of care; and CareAware, an EHR agnostic platform that facilitates connectivity of health care devices to EHRs. In addition, it offers a portfolio of clinical and financial healthcare information technology solutions, as well as departmental and care coordination solutions. Further, the company provides tech-enabled services, such as implementation and training, remote hosting, application management, revenue cycle, support and maintenance, health care data analysis, real-world evidence, clinical process optimization, transaction processing, employer health centers, and data-driven services; and complementary hardware and devices for third parties. It serves integrated delivery networks, physician groups and networks, managed care organizations, hospitals, medical centers, free-standing reference laboratories, home health agencies, blood banks, imaging centers, pharmacies, pharmaceutical manufacturers, employers, governments, and public health organizations. The company was founded in 1979 and is headquartered in North Kansas City, Missouri.

(Ad)

What people don’t know is that Roivant is capitalizing on a wealth secret that goes back over a century. There are a few other public companies who are as well. Only you don’t know it… because it’s not something they openly talk about. That’s why I made this presentation. I want to expose you to a wealth-building secret that you deserve to benefit from.

More Stock Ideas from MarketBeat